Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.
News|Articles|August 25, 2026
Report: Postpartum depression market expected to grow based on awareness, pipeline progress
Author(s)Joshua Fitch, Senior Editor
Fact checked by: Benjamin P. Saylor
With brexanolone withdrawn in 2025, zuranolone leads PPD treatment as luvesilocin and LPCN 1154 advance in trials.
Advertisement
Advertisement
The postpartum depression (PPD) treatment market is expected to grow through 2036 across the 7 major markets—the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan—according to a market analysis published by DelveInsight Business Research, LLP. In 2025, the total diagnosed prevalent cases of maternal PPD across these markets were approximately 1.3 million, a figure projected to rise over the forecast period.1
Related to this article
HPV vaccination before pregnancy was linked to lower odds of preterm birth in a Swedish study of 624,713 births.
Missed the rollout of ACOG's 2026 Maternal Immunization Schedule? This FAQ breaks down everything clinicians need to know about the new guidance.
The Preeclampsia Foundation released 2 videos on postpartum recovery and long-term health after HDP.
Experts discuss common patient concerns about vaccination in pregnancy and strategies to improve uptake.
Experts discuss how obstetric and pediatric clinicians can coordinate to protect newborns.
Experts review ACOG's 2026-27 guidance and the RSV window extension for pregnant and postpartum patients.
On September 9, 2026, certolizumab pegol received FDA Breakthrough Therapy Designation for APS pregnancy; Jane E. Salmon, MD, reviews the IMPACT trial results behind it.
Advertisement
Advertisement